Posted by Michael Wonder on 12 Jul 2023
Junshi Biosciences announces acceptance of the supplemental new drug application for toripalimab
11 July 2023 - Shanghai Junshi Biosciences announced that the supplemental new drug application for toripalimab, the company’s anti-PD-1 monoclonal antibody, in combination with axitinib for the first-line treatment of patients with unresectable or metastatic renal cell carcinoma, has been accepted by the National Medical Products Administration.
This supplemental new drug application is mainly based on the RENOTORCH study.
